BJU International is a prestigious academic journal specializing in the field of Urology, published by WILEY, one of the leading publishers in scientific literature. With an impressive impact factor and recognized as a Q1 journal in Urology for 2023, it ranks #7 out of 120 in the Scopus Medicine _ Urology category, placing it in the 94th percentile among its peers. Established in 1929 and with converged years from 1994 to 2024, BJU International provides a platform for groundbreaking research, clinical studies, and advancements in urological science. The journal is accessible in both print and online formats, catering to a global audience dedicated to enhancing urological practice and research. By fostering interdisciplinary dialogue and disseminating high-quality studies, BJU International plays a crucial role in advancing knowledge and improving patient care in the field of urology.

The Journal of Clinical Urology, published by SAGE Publications Ltd, is a prominent academic platform dedicated to advancing the field of urology and surgical medicine. With an ISSN of 2051-4158 and an E-ISSN of 2051-4166, this journal has been pivotal in disseminating cutting-edge research since its inception in 2008 and is set to continue through 2024. Although categorized in the Q4 quartile for both Surgery and Urology, and positioned in the 24th and 22nd percentiles respectively according to Scopus rankings, the journal remains an essential resource for professionals, researchers, and students who seek to understand clinical developments and innovative practices in urological surgery. While the journal does not operate under an Open Access model, it provides critical insights and valuable findings that significantly impact healthcare practices and patient outcomes in the urology field.

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

PROSTATE CANCER AND PROSTATIC DISEASES, published by SpringerNature, is a prestigious international journal dedicated to advancing knowledge in the fields of cancer research, oncology, and urology, as evidenced by its Q1 rankings in 2023. Established in 1997, this journal has become a vital resource for researchers, clinicians, and healthcare professionals, offering impactful research and clinical insights on prostate health and disease. With its focus on innovative studies and comprehensive reviews, it addresses critical challenges in the management and treatment of prostate cancer, driving improvements in patient care globally. The journal's standing is further supported by its impressive Scopus rankings, placing it in the top tier of its categories. Readers can access high-quality, peer-reviewed articles that contribute significantly to ongoing medical practices and improve therapeutic strategies for prostate-related health issues.

UROLOGY is a prestigious journal published by Elsevier Science Inc, renowned for disseminating high-quality research and reviews in the field of urology. With an ISSN of 0090-4295 and E-ISSN 1527-9995, this journal has been a trusted resource since its inception in 1973 and continues to provide insights into the latest advancements and clinical practices in urology, maintaining a category quartile of Q2 as of 2023. The journal ranks 50th out of 120 in the Scopus metrics for Medicine - Urology, placing it in the 58th percentile, which underscores its influence and relevance in the academic community. Although it is not structured as an open access journal, it offers a wealth of knowledge vital for researchers, healthcare professionals, and students alike, enabling them to stay abreast of evolving treatments and innovations in the field. As we move towards 2024, UROLOGY remains committed to advancing research and enhancing practices in urological care, fostering a collaborative environment among its readership.

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.

ONCOLOGIST is a premier, open-access journal published by Oxford University Press, advancing the field of cancer research since its inception in 1996. With an impressive H-Index and a prestigious placement within the Q1 category in Cancer Research, Medicine, and Oncology for 2023, ONCOLOGIST stands at the forefront of oncological science, boasting a Scopus rank of #55 out of 404 in Medicine and #47 out of 230 in Cancer Research. This journal not only disseminates cutting-edge research but also aims to foster multidisciplinary approaches that are critical for addressing the complex challenges faced in cancer therapy and survivorship. Be part of a vibrant community as you explore impactful research articles that contribute to the global conversation on cancer. ONCOLOGIST is dedicated to providing an accessible platform for authors and readers alike, ensuring that high-quality research is available to all stakeholders in the fight against cancer.

Indian Journal of Urology, published by Wolters Kluwer Medknow Publications, is a premier open-access journal dedicated to the field of urology, serving as a vital platform for researchers and clinicians to disseminate groundbreaking findings since its inception in 2001. With an ISSN of 0970-1591 and an E-ISSN of 1998-3824, this journal has established itself as a crucial resource for advancing knowledge in urological practices, particularly within the Indian context. Recognized in the 2023 Scopus Rankings with a classification of Q3 in Urology, it stands at a significant position (Rank #71 out of 120) with a 41st percentile performance, highlighting its role in contributing to the global discourse in urological medicine. The journal provides open access options, ensuring that high-quality research is readily available to a broad audience, fostering collaboration and innovation. Publishing significant studies from various converged years, including from 1984 to 1999 and more recently from 2006 to 2024, Indian Journal of Urology is essential for professionals seeking to stay updated with the latest advances and best practices in urology.

Urology Annals, published by Wolters Kluwer Medknow Publications, is a premier open-access journal dedicated to advancing the field of urology through high-quality research and clinical insights. Established in India in 2009, this journal serves as a vital platform for communication among urologists, researchers, and medical professionals, aiming to enhance understanding and innovation in urological sciences. With an ISSN of 0974-7796 and an E-ISSN of 0974-7834, the journal offers unrestricted access to its content, fostering knowledge dissemination and collaboration across the global medical community. Currently ranked in the Q3 category within urology and holding a Scopus rank of #79/120, Urology Annals showcases significant contributions that align with its mission to publish original research, reviews, and case reports that address contemporary challenges in urology. The journal's ongoing commitment to remaining a leading resource in the field is reflected through its convergence of years from 2010 to 2024, ensuring that it stays at the forefront of the latest urological advancements.